We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
IMMU 87.860.0%Oct 23 4:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: galt who wrote (53587)12/30/2019 11:41:36 AM
From: stockdoc773 Recommendations

Recommended By

  Read Replies (2) of 59038
There are lots of companies pursuing this space with a wide range of approaches. I cant pretend to fully understand all of them. What I like about FATE and NK is that they are both going for off the shelf allogeneic T cells, which cost 10k per dose, rather than autologous cells (like CAR T) which cost 100k. They also are modifying the cells with CD16 that allows the cells to recognize Ab and thereby can be targeted with an appropriate MAb (i.e. sacituzumab perhaps).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext